U.S. Vaccines Market Size, Share & Trends Analysis Report By Indication (Viral, Bacterial, Cancer Vaccines, Allergy), By Type (Subunit, Inactivated), By Payer Type, By Age Group, By Use Populations, By Usage/Administration Pattern, By Sales, And Segment Forecasts, 2026 - 2033
The U.S. vaccines market size was estimated at USD 26.00 billion in 2025 and is projected to reach USD 40.19 billion by 2033, growing at a CAGR of 5.40% from 2026 to 2033. The U.S. vaccines market is driven by rapid advancements in vaccine technologies and platform innovation.
The adoption of mRNA, recombinant, and vector-based approaches is accelerating the development of more effective and targeted vaccines across multiple disease areas. Continuous improvements in formulation, adjuvants, and delivery systems are enhancing immune response and overall product performance. Increasing focus on precision-based immunization is supporting the development of vaccines tailored to specific populations and disease risks.
Advancements in manufacturing technologies are improving scalability, reducing production timelines, and ensuring consistent quality. Strong research pipelines and faster development cycles are enabling quicker responses to emerging health threats. These factors are strengthening innovation capabilities and supporting sustained growth across the U.S. vaccines market. For instance, in January 2026, the U.S. Department of Health and Human Services announced that the Centers for Disease Control and Prevention had accepted recommendations to revise the U.S. childhood immunization schedule following a Presidential Memorandum issued on December 5, 2025. The scientific assessment reviewed immunization practices across 20 peer-developed nations and found that, in 2024, the United States provided protection against 18 diseases, compared to Denmark, which immunized children against 10 diseases. The analysis also indicated that the U.S. recommended more childhood vaccines and more than twice as many doses as some European countries, while retaining three fully insured immunization categories without cost sharing.
Growing demand for adult immunization is a key factor supporting market expansion in the United States. Rising prevalence of infectious diseases among aging populations is increasing the need for vaccines across multiple indications and risk groups. Higher awareness of preventive healthcare is encouraging routine vaccination among adults, including those with chronic conditions. Expansion of vaccination access through pharmacies, clinics, and workplace programs is improving convenience and uptake. Increasing incidence of respiratory infections such as influenza and respiratory syncytial virus is driving seasonal vaccine demand across regions. A longer life expectancy reinforces the importance of ongoing immunization beyond early life stages. For instance, in October 2025, the Centers for Disease Control and Prevention released an updated adult immunization schedule for individuals aged 19 years and older, covering four age cohorts, 1926 years, 2749 years, 5064 years, and 65 years and above. The schedule recommended one or more doses of the COVID-19 vaccine, one influenza dose annually, a three-dose tetanus, diphtheria, and pertussis primary series followed by one booster every 10 years and one additional dose during each pregnancy, as well as one respiratory syncytial virus vaccine dose for adults aged 5074 years and those aged 75 years or older, while hepatitis B vaccination was recommended through 59 years of age. These structured dosing intervals reinforced sustained adult vaccine demand and long-term revenue stability.
The market is further driven by portfolio expansion and evolving vaccination strategies across disease areas. Increasing development of combination vaccines is improving convenience, reducing the number of doses, and enhancing patient compliance. Regular updates in vaccine formulations are addressing emerging variants and changing epidemiological patterns across populations. Expansion into new therapeutic areas, including oncology and personalized vaccines, is creating additional growth opportunities. Improvements in supply chain systems are supporting efficient distribution, storage, and availability across healthcare settings. Increased collaboration across research networks is accelerating innovation and clinical development. For instance, in January 2026, Health Policy Watch reported that U.S. health authorities implemented a major revision to the childhood immunization schedule, reducing the number of diseases covered by routine vaccination from 17 to 11 and removing universal recommendations for six vaccines, including those for rotavirus, influenza, meningococcal disease, hepatitis A, hepatitis B, and respiratory syncytial virus. The revision also reduced the human papillomavirus vaccination requirement from two doses to one and followed a December 5, 2025 directive to review national practices against peer nations such as Denmark, Japan, Australia, Canada, and the United Kingdom, which recommended vaccines for 10, 14, and 15 diseases, respectively. Previous guidance indicated that children in the United States could receive approximately 35 to 36 doses across 18 years, while respiratory syncytial virus alone accounted for about 80,000 pediatric hospitalizations annually, highlighting the significant public health and market implications of schedule changes.
U.S. Vaccines Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. vaccines market report based on indication, type, payer type, age group, use populations, usage/administration pattern, and sales:
The adoption of mRNA, recombinant, and vector-based approaches is accelerating the development of more effective and targeted vaccines across multiple disease areas. Continuous improvements in formulation, adjuvants, and delivery systems are enhancing immune response and overall product performance. Increasing focus on precision-based immunization is supporting the development of vaccines tailored to specific populations and disease risks.
Advancements in manufacturing technologies are improving scalability, reducing production timelines, and ensuring consistent quality. Strong research pipelines and faster development cycles are enabling quicker responses to emerging health threats. These factors are strengthening innovation capabilities and supporting sustained growth across the U.S. vaccines market. For instance, in January 2026, the U.S. Department of Health and Human Services announced that the Centers for Disease Control and Prevention had accepted recommendations to revise the U.S. childhood immunization schedule following a Presidential Memorandum issued on December 5, 2025. The scientific assessment reviewed immunization practices across 20 peer-developed nations and found that, in 2024, the United States provided protection against 18 diseases, compared to Denmark, which immunized children against 10 diseases. The analysis also indicated that the U.S. recommended more childhood vaccines and more than twice as many doses as some European countries, while retaining three fully insured immunization categories without cost sharing.
Growing demand for adult immunization is a key factor supporting market expansion in the United States. Rising prevalence of infectious diseases among aging populations is increasing the need for vaccines across multiple indications and risk groups. Higher awareness of preventive healthcare is encouraging routine vaccination among adults, including those with chronic conditions. Expansion of vaccination access through pharmacies, clinics, and workplace programs is improving convenience and uptake. Increasing incidence of respiratory infections such as influenza and respiratory syncytial virus is driving seasonal vaccine demand across regions. A longer life expectancy reinforces the importance of ongoing immunization beyond early life stages. For instance, in October 2025, the Centers for Disease Control and Prevention released an updated adult immunization schedule for individuals aged 19 years and older, covering four age cohorts, 1926 years, 2749 years, 5064 years, and 65 years and above. The schedule recommended one or more doses of the COVID-19 vaccine, one influenza dose annually, a three-dose tetanus, diphtheria, and pertussis primary series followed by one booster every 10 years and one additional dose during each pregnancy, as well as one respiratory syncytial virus vaccine dose for adults aged 5074 years and those aged 75 years or older, while hepatitis B vaccination was recommended through 59 years of age. These structured dosing intervals reinforced sustained adult vaccine demand and long-term revenue stability.
The market is further driven by portfolio expansion and evolving vaccination strategies across disease areas. Increasing development of combination vaccines is improving convenience, reducing the number of doses, and enhancing patient compliance. Regular updates in vaccine formulations are addressing emerging variants and changing epidemiological patterns across populations. Expansion into new therapeutic areas, including oncology and personalized vaccines, is creating additional growth opportunities. Improvements in supply chain systems are supporting efficient distribution, storage, and availability across healthcare settings. Increased collaboration across research networks is accelerating innovation and clinical development. For instance, in January 2026, Health Policy Watch reported that U.S. health authorities implemented a major revision to the childhood immunization schedule, reducing the number of diseases covered by routine vaccination from 17 to 11 and removing universal recommendations for six vaccines, including those for rotavirus, influenza, meningococcal disease, hepatitis A, hepatitis B, and respiratory syncytial virus. The revision also reduced the human papillomavirus vaccination requirement from two doses to one and followed a December 5, 2025 directive to review national practices against peer nations such as Denmark, Japan, Australia, Canada, and the United Kingdom, which recommended vaccines for 10, 14, and 15 diseases, respectively. Previous guidance indicated that children in the United States could receive approximately 35 to 36 doses across 18 years, while respiratory syncytial virus alone accounted for about 80,000 pediatric hospitalizations annually, highlighting the significant public health and market implications of schedule changes.
U.S. Vaccines Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. vaccines market report based on indication, type, payer type, age group, use populations, usage/administration pattern, and sales:
- Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Viral Vaccines
- Hepatitis
- Influenza
- HPV
- MMR
- Rotavirus
- Herpes Zoster
- Japanese Encephalitis
- RSV
- Others
- Bacterial Vaccines
- Meningococcal Diseases
- Pneumococcal Diseases
- DPT
- Others
- Cancer Vaccines
- Allergy Vaccines
- Others
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Subunit Vaccines
- Recombinant Vaccines
- Conjugate Vaccines
- Toxoid Vaccines
- Inactivated
- Live Attenuated
- mRNA Vaccines
- Viral Vector Vaccines
- Payer Type Outlook (Revenue, USD Million, 2021 - 2033)
- Public Payer
- Medicare
- Medicaid
- Federal Programs
- Private Payers
- Commercial Insurance Plans
- Workplace Programs
- Out-of-Pocket / Self-Pay
- Others
- Age Group Outlook (Revenue, USD Million, 2021 - 2033)
- Pediatrics (0-17 years)
- Adults (18-64 years)
- Elderly (65+ years)
- Use Populations Outlook (Revenue, USD Million, 2021 - 2033)
- Workplace
- Schools
- Travelers
- Military & Special Occupations
- Others
- Usage/Administration Pattern Outlook (Revenue, USD Million, 2021 - 2033)
- Seasonal Vaccines
- Year-Round Vaccines
- Others
- Sales Outlook (Revenue, USD Million, 2021 - 2033)
- Tender-Based
- Direct Sales to Providers
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Indication
1.2.2. Type
1.2.3. Payer Type
1.2.4. Age Group
1.2.5. Use Populations
1.2.6. Usage/Administration Pattern
1.2.7. Sales
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. U.S. VACCINES MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
CHAPTER 4. U.S. VACCINE MARKET - MARKET ENTRY & REGULATORY LANDSCAPE
4.1. Regulatory Framework for Vaccines in the U.S.: CBER vs. CDER
4.2. Vaccine Approval Pathway in the U.S. (IND > BLA > GMP > Lot Consistency Trials)
4.2.1. Preclinical Development and IND Submission
4.2.2. Clinical Development Phases
4.2.3. Biologics License Application (BLA)
4.2.4. GMP Compliance and Manufacturing Validation
4.2.5. Lot Consistency Trials and Lot Release
4.3. Conditional Approvals, Accelerated Pathways, and Phase IV Requirements
4.3.1. Accelerated Approval and Priority Review
4.3.2. Emergency Use Authorization (EUA)
4.3.3. Phase IV Post-Marketing Requirements
4.3.4. Pharmacovigilance and Safety Monitoring
4.4. Clinical Trial Strategy for U.S. Vaccine Market Entry
4.4.1. FDA Expectations for Vaccine Trials
4.4.2. Ethnic and Demographic Representation
4.4.3. State-Level Enrollment Feasibility
4.4.4. Impact of U.S. Immunization Policy on Trial Design
4.4.5. Market Entry Strategy
4.5. Key Implications for Market Entry in the U.S. Vaccine Market
4.6. Analyst Perspective & Key Opinion Leader (KOL) Insights
CHAPTER 5. U.S. VACCINE MARKET - PRODUCT USAGE & RECOMMENDATIONS
5.1. Role of the Advisory Committee on Immunization Practices (ACIP)
5.1.1. ACIP Composition And Structure
5.1.2. Meeting Process And Decision Framework
5.1.3. Influence On Market Adoption
5.2. Adoption of ACIP Recommendations Across Providers, Payers, and States
5.2.1. Provider Adoption
5.2.2. Payer Adoption
5.2.3. State-Level Variation
5.2.4. Adoption Timeline Pattern
5.3. Reimbursement Dynamics in the U.S. Vaccine Market
5.3.1. Public Programs
5.3.2. Private Insurance Coverage
5.3.3. Out-Of-Pocket Costs
5.4. Mandatory Vaccination Requirements in the United States
5.4.1. School Entry Requirements
5.4.2. Workplace Requirements
5.4.3. Vaccination Recommendations For Elderly Populations
5.4.4. State-Level Policy Differences
5.5. Market Impact of Product Usage Policies
5.6. Analyst Perspective & Key Opinion Leader Insights
5.6.1. Role Of The Advisory Committee On Immunization Practices (ACIP)
5.6.1.1. Analyst Perspective
5.6.2. Adoption Of ACIP Recommendations Across Providers, Payers, And States
5.6.2.1. Analyst Perspective
5.6.3. Reimbursement Dynamics In The U.S. Vaccine Market
5.6.3.1. Analyst Perspective
5.6.4. Mandatory Vaccination Requirements In The United States
5.6.4.1. Analyst Perspective
5.6.5. Implications For Vaccine Market Uptake
CHAPTER 6. U.S. VACCINE MARKET - PHARMACOVIGILANCE & LEGAL FRAMEWORK
6.1. Post-marketing safety monitoring
6.1.1. Government Requirements
6.1.2. Adverse Event Reporting
6.1.3. Recall Process
6.1.4. Case Study Evaluation: Historical And Recent Safety Actions
6.2. Legal considerations
6.2.1. Manufacturer Vs. Distributor Responsibilities
6.2.2. Liability Exposure
6.3. Role of the National Vaccine Injury Compensation
6.4. Analyst Perspective & Key Opinion Leader Insights
CHAPTER 7. U.S. VACCINES MARKET: INDICATION BUSINESS ANALYSIS
7.1. Indication Market Share, 2025 & 2033
7.2. Indication Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
7.4. Viral Vaccines
7.4.1. Viral Vaccines Market, 2021 - 2033 (USD Million)
7.4.2. Hepatitis
7.4.2.1. Hepatitis Market, 2021 - 2033 (USD Million)
7.4.3. Influenza
7.4.3.1. Influenza Market, 2021 - 2033 (USD Million)
7.4.4. HPV
7.4.4.1. HPV Market, 2021 - 2033 (USD Million)
7.4.5. MMR
7.4.5.1. MMR Market, 2021 - 2033 (USD Million)
7.4.6. Rotavirus
7.4.6.1. Rotavirus Market, 2021 - 2033 (USD Million)
7.4.7. Herpes Zoster
7.4.7.1. Herpes Zoster Market, 2021 - 2033 (USD Million)
7.4.8. Japanese Encephalitis
7.4.8.1. Japanese Encephalitis Market, 2021 - 2033 (USD Million)
7.4.9. RSV
7.4.9.1. RSV Market, 2021 - 2033 (USD Million)
7.4.10. Others
7.4.10.1. Others Market, 2021 - 2033 (USD Million)
7.5. Bacterial Vaccines
7.5.1. Bacterial Vaccines Market, 2021 - 2033 (USD Million)
7.5.2. Meningococcal Diseases
7.5.2.1. Meningococcal Diseases Market, 2021 - 2033 (USD Million)
7.5.3. Pneumococcal Diseases
7.5.3.1. Pneumococcal Diseases Market, 2021 - 2033 (USD Million)
7.5.4. DPT
7.5.4.1. DPT Market, 2021 - 2033 (USD Million)
7.5.5. Others
7.5.5.1. Others Market, 2021 - 2033 (USD Million)
7.6. Cancer Vaccines
7.6.1. Cancer Vaccines Market, 2021 - 2033 (USD Million)
7.7. Allergy Vaccines
7.7.1. Allergy Vaccines Market, 2021 - 2033 (USD Million)
7.8. Others
7.8.1. Others Market, 2021 - 2033 (USD Million)
CHAPTER 8. U.S. VACCINES MARKET: TYPE BUSINESS ANALYSIS
8.1. Type Market Share, 2025 & 2033
8.2. Type Segment Dashboard
8.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
8.4. Subunit Vaccines
8.4.1. Subunit Vaccines Market, 2021 - 2033 (USD Million)
8.4.2. Recombinant Vaccines
8.4.2.1. Recombinant Vaccines Market, 2021 - 2033 (USD Million)
8.4.3. Conjugate Vaccines
8.4.3.1. Conjugate Vaccines Market, 2021 - 2033 (USD Million)
8.4.4. Toxoid Vaccines
8.4.4.1. Toxoid Vaccines Market, 2021 - 2033 (USD Million)
8.5. Inactivated
8.5.1. Inactivated Market, 2021 - 2033 (USD Million)
8.6. Live Attenuated
8.6.1. Live Attenuated Market, 2021 - 2033 (USD Million)
8.7. mRNA Vaccines
8.7.1. mRNA Vaccines Market, 2021 - 2033 (USD Million)
8.8. Viral Vector Vaccines
8.8.1. Viral Vector Vaccines Market, 2021 - 2033 (USD Million)
CHAPTER 9. U.S. VACCINES MARKET: PAYER TYPE BUSINESS ANALYSIS
9.1. Payer Type Market Share, 2025 & 2033
9.2. Payer Type Segment Dashboard
9.3. Market Size & Forecasts and Trend Analysis, by Payer type, 2021 to 2033 (USD Million)
9.4. Public Payer
9.4.1. Public Payer Market, 2021 - 2033 (USD Million)
9.4.2. Medicare
9.4.2.1. Medicare Market, 2021 - 2033 (USD Million)
9.4.3. Medicaid
9.4.3.1. Medicaid Market, 2021 - 2033 (USD Million)
9.4.4. Federal Programs
9.4.4.1. Federal Programs Market, 2021 - 2033 (USD Million)
9.5. Private Payers
9.5.1. Private Payers Market, 2021 - 2033 (USD Million)
9.5.2. Commercial Insurance Plans
9.5.2.1. Commercial Insurance Plans Market, 2021 - 2033 (USD Million)
9.5.3. Workplace Programs
9.5.3.1. Workplace Programs Market, 2021 - 2033 (USD Million)
9.6. Out-of-Pocket / Self-Pay
9.6.1. Out-of-Pocket / Self-Pay Market, 2021 - 2033 (USD Million)
9.7. Others
9.7.1. Others Market, 2021 - 2033 (USD Million)
CHAPTER 10. U.S. VACCINES MARKET: AGE GROUP BUSINESS ANALYSIS
10.1. Age Group Market Share, 2025 & 2033
10.2. Age Group Segment Dashboard
10.3. Market Size & Forecasts and Trend Analysis, by Age Group, 2021 to 2033 (USD Million)
10.4. Pediatrics (0-17 years)
10.4.1. Pediatrics (0-17 years) Market, 2021 - 2033 (USD Million)
10.5. Adults (18-64 years)
10.5.1. Adults (18-64 years) Market, 2021 - 2033 (USD Million)
10.6. Elderly (65+ years)
10.6.1. Elderly (65+ years) Market, 2021 - 2033 (USD Million)
CHAPTER 11. U.S. VACCINES MARKET: USE POPULATIONS BUSINESS ANALYSIS
11.1. Use Populations Market Share, 2025 & 2033
11.2. Use Populations Segment Dashboard
11.3. Market Size & Forecasts and Trend Analysis, by Use Populations, 2021 to 2033 (USD Million)
11.4. Workplace
11.4.1. Workplace Market, 2021 - 2033 (USD Million)
11.5. Schools
11.5.1. Schools Market, 2021 - 2033 (USD Million)
11.6. Travelers
11.6.1. Travelers Market, 2021 - 2033 (USD Million)
11.7. Military & Special Occupations
11.7.1. Military & Special Occupations Market, 2021 - 2033 (USD Million)
11.8. Others
11.8.1. Others Market, 2021 - 2033 (USD Million)
CHAPTER 12. U.S. VACCINES MARKET: USAGE/ADMINISTRATION PATTERN BUSINESS ANALYSIS
12.1. Usage/Administration Pattern Market Share, 2025 & 2033
12.2. Usage/Administration Pattern Segment Dashboard
12.3. Market Size & Forecasts and Trend Analysis, by Usage/Administration Pattern, 2021 to 2033 (USD Million)
12.4. Seasonal Vaccines
12.4.1. Seasonal Vaccines Market, 2021 - 2033 (USD Million)
12.5. Year-Round Vaccines
12.5.1. Year-Round Vaccines Market, 2021 - 2033 (USD Million)
12.6. Others
12.6.1. Others Market, 2021 - 2033 (USD Million)
CHAPTER 13. U.S. VACCINES MARKET: SALES BUSINESS ANALYSIS
13.1. Sales Market Share, 2025 & 2033
13.2. Sales Segment Dashboard
13.3. Market Size & Forecasts and Trend Analysis, by Sales, 2021 to 2033 (USD Million)
13.4. Tender-Based
13.4.1. Tender-Based Market, 2021 - 2033 (USD Million)
13.5. Direct Sales to Providers
13.5.1. Direct Sales to Providers Market, 2021 - 2033 (USD Million)
CHAPTER 14. COMPETITIVE LANDSCAPE
14.1. Participant Overview
14.2. Company Market Position Analysis
14.3. Company Categorization
14.4. Strategy Mapping
14.5. Company Profiles/Listing
14.5.1. Pfizer
14.5.1.1. Overview
14.5.1.2. Financial Performance
14.5.1.3. Product Benchmarking
14.5.1.4. Strategic Initiatives
14.5.2. GSK
14.5.2.1. Overview
14.5.2.2. Financial Performance
14.5.2.3. Product Benchmarking
14.5.2.4. Strategic Initiatives
14.5.3. Merck & Co. (MSD)
14.5.3.1. Overview
14.5.3.2. Financial Performance
14.5.3.3. Product Benchmarking
14.5.3.4. Strategic Initiatives
14.5.4. Sanofi
14.5.4.1. Overview
14.5.4.2. Financial Performance
14.5.4.3. Product Benchmarking
14.5.4.4. Strategic Initiatives
14.5.5. Moderna
14.5.5.1. Overview
14.5.5.2. Financial Performance
14.5.5.3. Product Benchmarking
14.5.5.4. Strategic Initiatives
14.5.6. Novavax
14.5.6.1. Overview
14.5.6.2. Financial Performance
14.5.6.3. Product Benchmarking
14.5.6.4. Strategic Initiatives
14.5.7. CSL Limited
14.5.7.1. Overview
14.5.7.2. Financial Performance
14.5.7.3. Product Benchmarking
14.5.7.4. Strategic Initiatives
14.5.8. AstraZeneca
14.5.8.1. Overview
14.5.8.2. Financial Performance
14.5.8.3. Product Benchmarking
14.5.8.4. Strategic Initiatives
14.5.9. Serum Institute of India
14.5.9.1. Overview
14.5.9.2. Financial Performance
14.5.9.3. Product Benchmarking
14.5.9.4. Strategic Initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Indication
1.2.2. Type
1.2.3. Payer Type
1.2.4. Age Group
1.2.5. Use Populations
1.2.6. Usage/Administration Pattern
1.2.7. Sales
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. U.S. VACCINES MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
CHAPTER 4. U.S. VACCINE MARKET - MARKET ENTRY & REGULATORY LANDSCAPE
4.1. Regulatory Framework for Vaccines in the U.S.: CBER vs. CDER
4.2. Vaccine Approval Pathway in the U.S. (IND > BLA > GMP > Lot Consistency Trials)
4.2.1. Preclinical Development and IND Submission
4.2.2. Clinical Development Phases
4.2.3. Biologics License Application (BLA)
4.2.4. GMP Compliance and Manufacturing Validation
4.2.5. Lot Consistency Trials and Lot Release
4.3. Conditional Approvals, Accelerated Pathways, and Phase IV Requirements
4.3.1. Accelerated Approval and Priority Review
4.3.2. Emergency Use Authorization (EUA)
4.3.3. Phase IV Post-Marketing Requirements
4.3.4. Pharmacovigilance and Safety Monitoring
4.4. Clinical Trial Strategy for U.S. Vaccine Market Entry
4.4.1. FDA Expectations for Vaccine Trials
4.4.2. Ethnic and Demographic Representation
4.4.3. State-Level Enrollment Feasibility
4.4.4. Impact of U.S. Immunization Policy on Trial Design
4.4.5. Market Entry Strategy
4.5. Key Implications for Market Entry in the U.S. Vaccine Market
4.6. Analyst Perspective & Key Opinion Leader (KOL) Insights
CHAPTER 5. U.S. VACCINE MARKET - PRODUCT USAGE & RECOMMENDATIONS
5.1. Role of the Advisory Committee on Immunization Practices (ACIP)
5.1.1. ACIP Composition And Structure
5.1.2. Meeting Process And Decision Framework
5.1.3. Influence On Market Adoption
5.2. Adoption of ACIP Recommendations Across Providers, Payers, and States
5.2.1. Provider Adoption
5.2.2. Payer Adoption
5.2.3. State-Level Variation
5.2.4. Adoption Timeline Pattern
5.3. Reimbursement Dynamics in the U.S. Vaccine Market
5.3.1. Public Programs
5.3.2. Private Insurance Coverage
5.3.3. Out-Of-Pocket Costs
5.4. Mandatory Vaccination Requirements in the United States
5.4.1. School Entry Requirements
5.4.2. Workplace Requirements
5.4.3. Vaccination Recommendations For Elderly Populations
5.4.4. State-Level Policy Differences
5.5. Market Impact of Product Usage Policies
5.6. Analyst Perspective & Key Opinion Leader Insights
5.6.1. Role Of The Advisory Committee On Immunization Practices (ACIP)
5.6.1.1. Analyst Perspective
5.6.2. Adoption Of ACIP Recommendations Across Providers, Payers, And States
5.6.2.1. Analyst Perspective
5.6.3. Reimbursement Dynamics In The U.S. Vaccine Market
5.6.3.1. Analyst Perspective
5.6.4. Mandatory Vaccination Requirements In The United States
5.6.4.1. Analyst Perspective
5.6.5. Implications For Vaccine Market Uptake
CHAPTER 6. U.S. VACCINE MARKET - PHARMACOVIGILANCE & LEGAL FRAMEWORK
6.1. Post-marketing safety monitoring
6.1.1. Government Requirements
6.1.2. Adverse Event Reporting
6.1.3. Recall Process
6.1.4. Case Study Evaluation: Historical And Recent Safety Actions
6.2. Legal considerations
6.2.1. Manufacturer Vs. Distributor Responsibilities
6.2.2. Liability Exposure
6.3. Role of the National Vaccine Injury Compensation
6.4. Analyst Perspective & Key Opinion Leader Insights
CHAPTER 7. U.S. VACCINES MARKET: INDICATION BUSINESS ANALYSIS
7.1. Indication Market Share, 2025 & 2033
7.2. Indication Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
7.4. Viral Vaccines
7.4.1. Viral Vaccines Market, 2021 - 2033 (USD Million)
7.4.2. Hepatitis
7.4.2.1. Hepatitis Market, 2021 - 2033 (USD Million)
7.4.3. Influenza
7.4.3.1. Influenza Market, 2021 - 2033 (USD Million)
7.4.4. HPV
7.4.4.1. HPV Market, 2021 - 2033 (USD Million)
7.4.5. MMR
7.4.5.1. MMR Market, 2021 - 2033 (USD Million)
7.4.6. Rotavirus
7.4.6.1. Rotavirus Market, 2021 - 2033 (USD Million)
7.4.7. Herpes Zoster
7.4.7.1. Herpes Zoster Market, 2021 - 2033 (USD Million)
7.4.8. Japanese Encephalitis
7.4.8.1. Japanese Encephalitis Market, 2021 - 2033 (USD Million)
7.4.9. RSV
7.4.9.1. RSV Market, 2021 - 2033 (USD Million)
7.4.10. Others
7.4.10.1. Others Market, 2021 - 2033 (USD Million)
7.5. Bacterial Vaccines
7.5.1. Bacterial Vaccines Market, 2021 - 2033 (USD Million)
7.5.2. Meningococcal Diseases
7.5.2.1. Meningococcal Diseases Market, 2021 - 2033 (USD Million)
7.5.3. Pneumococcal Diseases
7.5.3.1. Pneumococcal Diseases Market, 2021 - 2033 (USD Million)
7.5.4. DPT
7.5.4.1. DPT Market, 2021 - 2033 (USD Million)
7.5.5. Others
7.5.5.1. Others Market, 2021 - 2033 (USD Million)
7.6. Cancer Vaccines
7.6.1. Cancer Vaccines Market, 2021 - 2033 (USD Million)
7.7. Allergy Vaccines
7.7.1. Allergy Vaccines Market, 2021 - 2033 (USD Million)
7.8. Others
7.8.1. Others Market, 2021 - 2033 (USD Million)
CHAPTER 8. U.S. VACCINES MARKET: TYPE BUSINESS ANALYSIS
8.1. Type Market Share, 2025 & 2033
8.2. Type Segment Dashboard
8.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
8.4. Subunit Vaccines
8.4.1. Subunit Vaccines Market, 2021 - 2033 (USD Million)
8.4.2. Recombinant Vaccines
8.4.2.1. Recombinant Vaccines Market, 2021 - 2033 (USD Million)
8.4.3. Conjugate Vaccines
8.4.3.1. Conjugate Vaccines Market, 2021 - 2033 (USD Million)
8.4.4. Toxoid Vaccines
8.4.4.1. Toxoid Vaccines Market, 2021 - 2033 (USD Million)
8.5. Inactivated
8.5.1. Inactivated Market, 2021 - 2033 (USD Million)
8.6. Live Attenuated
8.6.1. Live Attenuated Market, 2021 - 2033 (USD Million)
8.7. mRNA Vaccines
8.7.1. mRNA Vaccines Market, 2021 - 2033 (USD Million)
8.8. Viral Vector Vaccines
8.8.1. Viral Vector Vaccines Market, 2021 - 2033 (USD Million)
CHAPTER 9. U.S. VACCINES MARKET: PAYER TYPE BUSINESS ANALYSIS
9.1. Payer Type Market Share, 2025 & 2033
9.2. Payer Type Segment Dashboard
9.3. Market Size & Forecasts and Trend Analysis, by Payer type, 2021 to 2033 (USD Million)
9.4. Public Payer
9.4.1. Public Payer Market, 2021 - 2033 (USD Million)
9.4.2. Medicare
9.4.2.1. Medicare Market, 2021 - 2033 (USD Million)
9.4.3. Medicaid
9.4.3.1. Medicaid Market, 2021 - 2033 (USD Million)
9.4.4. Federal Programs
9.4.4.1. Federal Programs Market, 2021 - 2033 (USD Million)
9.5. Private Payers
9.5.1. Private Payers Market, 2021 - 2033 (USD Million)
9.5.2. Commercial Insurance Plans
9.5.2.1. Commercial Insurance Plans Market, 2021 - 2033 (USD Million)
9.5.3. Workplace Programs
9.5.3.1. Workplace Programs Market, 2021 - 2033 (USD Million)
9.6. Out-of-Pocket / Self-Pay
9.6.1. Out-of-Pocket / Self-Pay Market, 2021 - 2033 (USD Million)
9.7. Others
9.7.1. Others Market, 2021 - 2033 (USD Million)
CHAPTER 10. U.S. VACCINES MARKET: AGE GROUP BUSINESS ANALYSIS
10.1. Age Group Market Share, 2025 & 2033
10.2. Age Group Segment Dashboard
10.3. Market Size & Forecasts and Trend Analysis, by Age Group, 2021 to 2033 (USD Million)
10.4. Pediatrics (0-17 years)
10.4.1. Pediatrics (0-17 years) Market, 2021 - 2033 (USD Million)
10.5. Adults (18-64 years)
10.5.1. Adults (18-64 years) Market, 2021 - 2033 (USD Million)
10.6. Elderly (65+ years)
10.6.1. Elderly (65+ years) Market, 2021 - 2033 (USD Million)
CHAPTER 11. U.S. VACCINES MARKET: USE POPULATIONS BUSINESS ANALYSIS
11.1. Use Populations Market Share, 2025 & 2033
11.2. Use Populations Segment Dashboard
11.3. Market Size & Forecasts and Trend Analysis, by Use Populations, 2021 to 2033 (USD Million)
11.4. Workplace
11.4.1. Workplace Market, 2021 - 2033 (USD Million)
11.5. Schools
11.5.1. Schools Market, 2021 - 2033 (USD Million)
11.6. Travelers
11.6.1. Travelers Market, 2021 - 2033 (USD Million)
11.7. Military & Special Occupations
11.7.1. Military & Special Occupations Market, 2021 - 2033 (USD Million)
11.8. Others
11.8.1. Others Market, 2021 - 2033 (USD Million)
CHAPTER 12. U.S. VACCINES MARKET: USAGE/ADMINISTRATION PATTERN BUSINESS ANALYSIS
12.1. Usage/Administration Pattern Market Share, 2025 & 2033
12.2. Usage/Administration Pattern Segment Dashboard
12.3. Market Size & Forecasts and Trend Analysis, by Usage/Administration Pattern, 2021 to 2033 (USD Million)
12.4. Seasonal Vaccines
12.4.1. Seasonal Vaccines Market, 2021 - 2033 (USD Million)
12.5. Year-Round Vaccines
12.5.1. Year-Round Vaccines Market, 2021 - 2033 (USD Million)
12.6. Others
12.6.1. Others Market, 2021 - 2033 (USD Million)
CHAPTER 13. U.S. VACCINES MARKET: SALES BUSINESS ANALYSIS
13.1. Sales Market Share, 2025 & 2033
13.2. Sales Segment Dashboard
13.3. Market Size & Forecasts and Trend Analysis, by Sales, 2021 to 2033 (USD Million)
13.4. Tender-Based
13.4.1. Tender-Based Market, 2021 - 2033 (USD Million)
13.5. Direct Sales to Providers
13.5.1. Direct Sales to Providers Market, 2021 - 2033 (USD Million)
CHAPTER 14. COMPETITIVE LANDSCAPE
14.1. Participant Overview
14.2. Company Market Position Analysis
14.3. Company Categorization
14.4. Strategy Mapping
14.5. Company Profiles/Listing
14.5.1. Pfizer
14.5.1.1. Overview
14.5.1.2. Financial Performance
14.5.1.3. Product Benchmarking
14.5.1.4. Strategic Initiatives
14.5.2. GSK
14.5.2.1. Overview
14.5.2.2. Financial Performance
14.5.2.3. Product Benchmarking
14.5.2.4. Strategic Initiatives
14.5.3. Merck & Co. (MSD)
14.5.3.1. Overview
14.5.3.2. Financial Performance
14.5.3.3. Product Benchmarking
14.5.3.4. Strategic Initiatives
14.5.4. Sanofi
14.5.4.1. Overview
14.5.4.2. Financial Performance
14.5.4.3. Product Benchmarking
14.5.4.4. Strategic Initiatives
14.5.5. Moderna
14.5.5.1. Overview
14.5.5.2. Financial Performance
14.5.5.3. Product Benchmarking
14.5.5.4. Strategic Initiatives
14.5.6. Novavax
14.5.6.1. Overview
14.5.6.2. Financial Performance
14.5.6.3. Product Benchmarking
14.5.6.4. Strategic Initiatives
14.5.7. CSL Limited
14.5.7.1. Overview
14.5.7.2. Financial Performance
14.5.7.3. Product Benchmarking
14.5.7.4. Strategic Initiatives
14.5.8. AstraZeneca
14.5.8.1. Overview
14.5.8.2. Financial Performance
14.5.8.3. Product Benchmarking
14.5.8.4. Strategic Initiatives
14.5.9. Serum Institute of India
14.5.9.1. Overview
14.5.9.2. Financial Performance
14.5.9.3. Product Benchmarking
14.5.9.4. Strategic Initiatives
LIST OF TABLES
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. U.S. vaccines market, by indication, 2021 - 2033 (USD Million)
Table 4. U.S. vaccines market, by type, 2021 - 2033 (USD Million)
Table 5. U.S. vaccines market, by payer type, 2021 - 2033 (USD Million)
Table 6. U.S. vaccines market, by age group, 2021 - 2033 (USD Million)
Table 7. U.S. vaccines market, by use populations, 2021 - 2033 (USD Million)
Table 8. U.S. vaccines market, by usage/administration pattern, 2021 - 2033 (USD Million)
Table 9. U.S. vaccines market, by sales, 2021 - 2033
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. U.S. vaccines market, by indication, 2021 - 2033 (USD Million)
Table 4. U.S. vaccines market, by type, 2021 - 2033 (USD Million)
Table 5. U.S. vaccines market, by payer type, 2021 - 2033 (USD Million)
Table 6. U.S. vaccines market, by age group, 2021 - 2033 (USD Million)
Table 7. U.S. vaccines market, by use populations, 2021 - 2033 (USD Million)
Table 8. U.S. vaccines market, by usage/administration pattern, 2021 - 2033 (USD Million)
Table 9. U.S. vaccines market, by sales, 2021 - 2033
LIST OF FIGURES
Fig. 1 U.S. vaccines market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Competitive landscape
Fig. 10 U.S. vaccines market dynamics
Fig. 11 U.S. vaccines market: Porter’s five forces analysis
Fig. 12 U.S. vaccines market: PESTLE analysis
Fig. 13 Indication market, 2021 - 2033 (USD Million)
Fig. 14 Viral Vaccines market, 2021 - 2033 (USD Million)
Fig. 15 Hepatitis market, 2021 - 2033 (USD Million)
Fig. 16 Influenza market, 2021 - 2033 (USD Million)
Fig. 17 HPV market, 2021 - 2033 (USD Million)
Fig. 18 MMR market, 2021 - 2033 (USD Million)
Fig. 19 Rotavirus market, 2021 - 2033 (USD Million)
Fig. 20 Herpes Zoster market, 2021 - 2033 (USD Million)
Fig. 21 Japanese Encephalitis market, 2021 - 2033 (USD Million)
Fig. 22 RSV market, 2021 - 2033 (USD Million)
Fig. 23 Others market, 2021 - 2033 (USD Million)
Fig. 24 Bacterial Vaccines market, 2021 - 2033 (USD Million)
Fig. 25 Meningococcal Diseases market, 2021 - 2033 (USD Million)
Fig. 26 Pneumococcal Diseases market, 2021 - 2033 (USD Million)
Fig. 27 DPT market, 2021 - 2033 (USD Million)
Fig. 28 Others market, 2021 - 2033 (USD Million)
Fig. 29 Cancer Vaccines market, 2021 - 2033 (USD Million)
Fig. 30 Allergy Vaccines market, 2021 - 2033 (USD Million)
Fig. 31 Others market, 2021 - 2033 (USD Million)
Fig. 32 Type market, 2021 - 2033 (USD Million)
Fig. 33 Subunit Vaccines market, 2021 - 2033 (USD Million)
Fig. 34 Recombinant Vaccines market, 2021 - 2033 (USD Million)
Fig. 35 Conjugate Vaccines market, 2021 - 2033 (USD Million)
Fig. 36 Toxoid Vaccines market, 2021 - 2033 (USD Million)
Fig. 37 Inactivated market, 2021 - 2033 (USD Million)
Fig. 38 Live Attenuated market, 2021 - 2033 (USD Million)
Fig. 39 mRNA Vaccines market, 2021 - 2033 (USD Million)
Fig. 40 Viral Vector Vaccines market, 2021 - 2033 (USD Million)
Fig. 41 Payer Type market, 2021 - 2033 (USD Million)
Fig. 42 Public Payer market, 2021 - 2033 (USD Million)
Fig. 43 Medicare market, 2021 - 2033 (USD Million)
Fig. 44 Medicaid market, 2021 - 2033 (USD Million)
Fig. 45 Federal Programs market, 2021 - 2033 (USD Million)
Fig. 46 Private Payers market, 2021 - 2033 (USD Million)
Fig. 47 Commercial Insurance Plans market, 2021 - 2033 (USD Million)
Fig. 48 Workplace Programs market, 2021 - 2033 (USD Million)
Fig. 49 Out-of-Pocket / Self-Pay market, 2021 - 2033 (USD Million)
Fig. 50 Others market, 2021 - 2033 (USD Million)
Fig. 51 Age Group market, 2021 - 2033 (USD Million)
Fig. 52 Pediatrics (0-17 years) market, 2021 - 2033 (USD Million)
Fig. 53 Adults (18-64 years) market, 2021 - 2033 (USD Million)
Fig. 54 Elderly (65+ years) market, 2021 - 2033 (USD Million)
Fig. 55 Use Populations market, 2021 - 2033 (USD Million)
Fig. 56 Workplace market, 2021 - 2033 (USD Million)
Fig. 57 Schools market, 2021 - 2033 (USD Million)
Fig. 58 Travelers market, 2021 - 2033 (USD Million)
Fig. 59 Military & Special Occupations market, 2021 - 2033 (USD Million)
Fig. 60 Others market, 2021 - 2033 (USD Million)
Fig. 61 Usage/Administration Pattern market, 2021 - 2033 (USD Million)
Fig. 62 Seasonal Vaccines market, 2021 - 2033 (USD Million)
Fig. 63 Year-Round Vaccines market, 2021 - 2033 (USD Million)
Fig. 64 Others market, 2021 - 2033 (USD Million)
Fig. 65 Sales market, 2021 - 2033 (USD Million)
Fig. 66 Tender-Based market, 2021 - 2033 (USD Million)
Fig. 67 Direct Sales to Providers market, 2021 - 2033 (USD Million)
Fig. 68 Company categorization
Fig. 69 Company market position analysis
Fig. 70 Strategic framework
Fig. 1 U.S. vaccines market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Competitive landscape
Fig. 10 U.S. vaccines market dynamics
Fig. 11 U.S. vaccines market: Porter’s five forces analysis
Fig. 12 U.S. vaccines market: PESTLE analysis
Fig. 13 Indication market, 2021 - 2033 (USD Million)
Fig. 14 Viral Vaccines market, 2021 - 2033 (USD Million)
Fig. 15 Hepatitis market, 2021 - 2033 (USD Million)
Fig. 16 Influenza market, 2021 - 2033 (USD Million)
Fig. 17 HPV market, 2021 - 2033 (USD Million)
Fig. 18 MMR market, 2021 - 2033 (USD Million)
Fig. 19 Rotavirus market, 2021 - 2033 (USD Million)
Fig. 20 Herpes Zoster market, 2021 - 2033 (USD Million)
Fig. 21 Japanese Encephalitis market, 2021 - 2033 (USD Million)
Fig. 22 RSV market, 2021 - 2033 (USD Million)
Fig. 23 Others market, 2021 - 2033 (USD Million)
Fig. 24 Bacterial Vaccines market, 2021 - 2033 (USD Million)
Fig. 25 Meningococcal Diseases market, 2021 - 2033 (USD Million)
Fig. 26 Pneumococcal Diseases market, 2021 - 2033 (USD Million)
Fig. 27 DPT market, 2021 - 2033 (USD Million)
Fig. 28 Others market, 2021 - 2033 (USD Million)
Fig. 29 Cancer Vaccines market, 2021 - 2033 (USD Million)
Fig. 30 Allergy Vaccines market, 2021 - 2033 (USD Million)
Fig. 31 Others market, 2021 - 2033 (USD Million)
Fig. 32 Type market, 2021 - 2033 (USD Million)
Fig. 33 Subunit Vaccines market, 2021 - 2033 (USD Million)
Fig. 34 Recombinant Vaccines market, 2021 - 2033 (USD Million)
Fig. 35 Conjugate Vaccines market, 2021 - 2033 (USD Million)
Fig. 36 Toxoid Vaccines market, 2021 - 2033 (USD Million)
Fig. 37 Inactivated market, 2021 - 2033 (USD Million)
Fig. 38 Live Attenuated market, 2021 - 2033 (USD Million)
Fig. 39 mRNA Vaccines market, 2021 - 2033 (USD Million)
Fig. 40 Viral Vector Vaccines market, 2021 - 2033 (USD Million)
Fig. 41 Payer Type market, 2021 - 2033 (USD Million)
Fig. 42 Public Payer market, 2021 - 2033 (USD Million)
Fig. 43 Medicare market, 2021 - 2033 (USD Million)
Fig. 44 Medicaid market, 2021 - 2033 (USD Million)
Fig. 45 Federal Programs market, 2021 - 2033 (USD Million)
Fig. 46 Private Payers market, 2021 - 2033 (USD Million)
Fig. 47 Commercial Insurance Plans market, 2021 - 2033 (USD Million)
Fig. 48 Workplace Programs market, 2021 - 2033 (USD Million)
Fig. 49 Out-of-Pocket / Self-Pay market, 2021 - 2033 (USD Million)
Fig. 50 Others market, 2021 - 2033 (USD Million)
Fig. 51 Age Group market, 2021 - 2033 (USD Million)
Fig. 52 Pediatrics (0-17 years) market, 2021 - 2033 (USD Million)
Fig. 53 Adults (18-64 years) market, 2021 - 2033 (USD Million)
Fig. 54 Elderly (65+ years) market, 2021 - 2033 (USD Million)
Fig. 55 Use Populations market, 2021 - 2033 (USD Million)
Fig. 56 Workplace market, 2021 - 2033 (USD Million)
Fig. 57 Schools market, 2021 - 2033 (USD Million)
Fig. 58 Travelers market, 2021 - 2033 (USD Million)
Fig. 59 Military & Special Occupations market, 2021 - 2033 (USD Million)
Fig. 60 Others market, 2021 - 2033 (USD Million)
Fig. 61 Usage/Administration Pattern market, 2021 - 2033 (USD Million)
Fig. 62 Seasonal Vaccines market, 2021 - 2033 (USD Million)
Fig. 63 Year-Round Vaccines market, 2021 - 2033 (USD Million)
Fig. 64 Others market, 2021 - 2033 (USD Million)
Fig. 65 Sales market, 2021 - 2033 (USD Million)
Fig. 66 Tender-Based market, 2021 - 2033 (USD Million)
Fig. 67 Direct Sales to Providers market, 2021 - 2033 (USD Million)
Fig. 68 Company categorization
Fig. 69 Company market position analysis
Fig. 70 Strategic framework
